CORDIS
EU research results

CORDIS

English EN

Understanding chronic pain and improving its treatment

Objective

We will establish an international team of leading researchers and clinicians (EuroPain) to undertake multidisciplinary translational research which will: 1) increase the understanding of chronic pain mechanisms; 2)facilitate the development of novel analgesic drugs; and 3) improve the treatment of chronic pain patients.
Nineteen researchers drawn from the London Pain Consortium, the Danish Pain Research Centre, the German Pain Network and a Spanish research-intensive SME centre will form a ‘meta’ consortium with complementary expertise. The LPC is mainly laboratory based with a spectrum of skills from molecular biology and bioinformatics through integrated research in animal models to human physiological research, including imaging.The German and Danish groups have large databases on neuropathic and postsurgical pain, respectively, while the Spanish centre offers expertise in human microneurography. We will undertake a series of six interlinked and mutually supportive programs of experimental research, underpinned and supported by a coordinated training and bioinformatics facility. These programs will form a series of workpackages each delivered through collaboration of network laboratories to bring together multiple techniques and considerable expertise to each area. In addition, there will be considerable synergies between the programs. The programs, which fully address the Call, will focus on: Neurobiological mechanisms of chronic pain; Improving animal models of pain; Translational pain models in humans; Mechanisms and assessment of pain in patients; Risk factors for chronic pain.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

H. LUNDBECK AS

Address

Ottiliavej 7-9
2500 Valby

Denmark

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Principal Investigator

Märta Segerdahl (Dr)

Administrative Contact

Ejner Knud Moltzen (Mr)

Participants (25)

Sort alphabetically

Sort by EU Contribution

Expand all

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 402 298

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 760 567

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 383 409

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 532 852

NEUROSCIENCE TECHNOLOGIES SLP

Spain

EU Contribution

€ 98 364

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

Germany

EU Contribution

€ 425 871

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Germany

EU Contribution

€ 436 430

KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN

Germany

EU Contribution

€ 412 141

Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH

Germany

EU Contribution

€ 445 793

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Germany

EU Contribution

€ 415 741

AARHUS UNIVERSITETSHOSPITAL

Denmark

EU Contribution

€ 1 334 952

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 359 199

SYDDANSK UNIVERSITET

Denmark

EU Contribution

€ 209 726

BOEHRINGER INGELHEIM INTERNATIONALGMBH

Germany

PFIZER LIMITED

United Kingdom

Eli Lilly and Company Limited

United Kingdom

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

ESTEVE PHARMACEUTICALS, SA

Spain

UCB PHARMA SA

Belgium

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT

France

ASTRAZENECA AB

Sweden

ABBVIE DEUTSCHLAND GMBH & CO KG

Germany

ASTELLAS PHARMA EUROPE BV

Netherlands

GRUENENTHAL GMBH

Germany

Neuroscience Technologies Limited

United Kingdom

EU Contribution

€ 12 000

Project information

Grant agreement ID: 115007

Status

Closed project

  • Start date

    1 October 2009

  • End date

    30 September 2015

Funded under:

FP7-JTI

  • Overall budget:

    € 22 244 283

  • EU contribution

    € 6 229 343

Coordinated by:

H. LUNDBECK AS

Denmark